Literature DB >> 2957125

Direct radioimmunoassay of human plasma atrial natriuretic peptide in various normal and pathophysiological states: increase in renal and cardiac failure during exercise.

M Morris, M Cain, A Russell, J Elliott, J Chalmers.   

Abstract

We have used a sensitive direct radioimmunoassay to study the effects of exercise on plasma atrial natriuretic peptide (ANP) concentrations in man. Plasma ANP concentration increased three-fold in sixteen patients undergoing bicycle ergometer electrocardiographic tests for the investigation of chest pain. Resting ANP concentrations were higher in those patients in whom there was more evidence of heart disease, such as a positive exercise test, treatment with a beta blocker or history of myocardial infarction, although exercise resulted in increased ANP in both groups. We also confirm the increased plasma ANP concentration observed in patients with congestive cardiac failure and renal failure. In nine patients with renal failure routine haemodialysis was accompanied by a 30 per cent reduction in plasma ANP concentration. Plasma ANP concentrations were similar in treated hypertensive patients, untreated borderline hypertensive patients and normotensive subjects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957125     DOI: 10.3109/10641968709161445

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  3 in total

Review 1.  Effects of exercise on atrial natriuretic factor. Release mechanisms and implications for fluid homeostasis.

Authors:  B J Freund; C E Wade; J R Claybaugh
Journal:  Sports Med       Date:  1988-12       Impact factor: 11.136

2.  Atrial natriuretic factor responses to submaximal and maximal exercise.

Authors:  K Mandroukas; A Zakas; N Aggelopoulou; K Christoulas; G Abatzides; M Karamouzis
Journal:  Br J Sports Med       Date:  1995-12       Impact factor: 13.800

3.  Effect of captopril on functional, physiological and biochemical outcome criteria in aged heart failure patients.

Authors:  C J O'Neill; A Charlett; R J Dobbs; A A Deshmukh; S G Bowes; C Weller; P W Nicholson; J S Milledge; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.